TickerGuard
Buy Day today: Neutral (58) Mixed market breadth · no major macro event
HWKN

Hawkins Inc

Basic Materials · Specialty Chemicals

131.10$ +2.3% vs. previous close Closing price · As of: Aug 14, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Hawkins Inc (HWKN). It shows which part of the business is growing — and which one is holding it back.

Revenue by business segment

Revenue by business segment — HWKN
Segment Q2 2025 Q2 2026
Water Treatment [Member] $149.6M 51.0% $158.3M 50.1%
Food & Health Sciences $89.2M 30.4% $97.3M 30.8%
Industrial Solutions [Member] $54.5M 18.6% $60.1M 19.0%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Operating income — HWKN
Segment Q2 2025 Q2 2026
Water Treatment [Member] $24.7M 16.5% $21.8M 13.8%
Food & Health Sciences $11.0M 12.3% $11.2M 11.6%
Industrial Solutions [Member] $5.7M 10.5% $5.6M 9.3%

Large figure: segment operating income. Below it the margin, that is operating income measured against the revenue of the same segment.

Revenue by product line

Revenue by product line — HWKN
Segment Q2 2025 Q2 2026
Manufactured, blended or repackaged products $177.7M 60.6% $185.9M 58.9%
Nutrition $35.3M 12.0% $37.1M 11.7%
Bulk products $23.8M 8.1% $28.9M 9.2%
Agricultural $21.5M 7.3% $27.9M 8.8%
Food $26.1M 8.9% $24.3M 7.7%
Pharmaceutical $5.6M 1.9% $7.0M 2.2%
Other [Member] $3.4M 1.1% $4.6M 1.5%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 14, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?